LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A | A443654 | 10.0 | uM | LJP6 | 72 | hr | 1694 | 538 | 11155 | 0.0483 | -0.1222 |
| MCF 10A | OSI-027 | 10.0 | uM | LJP6 | 72 | hr | 1694 | 2582 | 11155 | 0.2315 | 0.0939 |
| MCF 10A | XMD11-85h | 10.0 | uM | LJP6 | 72 | hr | 1694 | 9171 | 11155 | 0.8221 | 0.7902 |
| MCF 10A | HG-6-64-01 | 10.0 | uM | LJP6 | 72 | hr | 1694 | 2052 | 11155 | 0.1840 | 0.0378 |
| MCF 10A | WH-4-025 | 10.0 | uM | LJP5 | 72 | hr | 1694 | 3251 | 11155 | 0.2915 | 0.1646 |
| MCF 10A | WZ-4-145 | 10.0 | uM | LJP6 | 72 | hr | 1694 | 2277 | 11155 | 0.2041 | 0.0616 |
| MCF 10A | XMD16-144 | 10.0 | uM | LJP5 | 72 | hr | 1694 | 1290 | 11155 | 0.1157 | -0.0427 |
| MCF 10A | Brivanib | 10.0 | uM | LJP5 | 72 | hr | 1694 | 3918 | 11155 | 0.3512 | 0.2350 |
| MCF 10A | Buparlisib | 10.0 | uM | LJP5 | 72 | hr | 1694 | 615 | 11155 | 0.0551 | -0.1141 |
| MCF 10A | BX-912 | 10.0 | uM | LJP5 | 72 | hr | 1694 | 1956 | 11155 | 0.1754 | 0.0277 |
| MCF 10A | Canertinib | 10.0 | uM | LJP6 | 72 | hr | 1694 | 115 | 11155 | 0.0104 | -0.1668 |
| MCF 10A | Celastrol | 10.0 | uM | LJP6 | 72 | hr | 1694 | 804 | 11155 | 0.0721 | -0.0941 |
| MCF 10A | CGP60474 | 10.0 | uM | LJP5 | 72 | hr | 1694 | 500 | 11155 | 0.0448 | -0.1262 |
| MCF 10A | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 1694 | 439 | 11155 | 0.0394 | -0.1326 |
| MCF 10A | CHIR-99021 | 10.0 | uM | LJP6 | 72 | hr | 1694 | 9109 | 11155 | 0.8166 | 0.7837 |
| MCF 10A | CP724714 | 10.0 | uM | LJP5 | 72 | hr | 1694 | 10255 | 11155 | 0.9193 | 0.9048 |
| MCF 10A | CP466722 | 10.0 | uM | LJP5 | 72 | hr | 1694 | 11084 | 11155 | 0.9936 | 0.9924 |
| MCF 10A | Crizotinib | 10.0 | uM | LJP5 | 72 | hr | 1694 | 2103 | 11155 | 0.1885 | 0.0432 |
| MCF 10A | Momelotinib | 10.0 | uM | LJP5 | 72 | hr | 1694 | 2672 | 11155 | 0.2396 | 0.1034 |
| MCF 10A | Dasatinib | 10.0 | uM | LJP5 | 72 | hr | 1694 | 1251 | 11155 | 0.1122 | -0.0468 |
| MCF 10A | Dasatinib | 10.0 | uM | LJP6 | 72 | hr | 1694 | 871 | 11155 | 0.0781 | -0.0869 |
| MCF 10A | Dovitinib | 10.0 | uM | LJP5 | 72 | hr | 1694 | 1920 | 11155 | 0.1721 | 0.0239 |
| MCF 10A | Enzastaurin | 10.0 | uM | LJP5 | 72 | hr | 1694 | 12028 | 11155 | 1.0782 | 1.0922 |
| MCF 10A | Erlotinib | 10.0 | uM | LJP5 | 72 | hr | 1694 | 2603 | 11155 | 0.2333 | 0.0960 |
| MCF 10A | Foretinib | 10.0 | uM | LJP5 | 72 | hr | 1694 | 1417 | 11155 | 0.1270 | -0.0293 |